In our study, we identified 78 reports of oligohydramnios among patients exposed to anti-ERBB2 agents during pregnancy (23.8%).5,12,13 This result confirms, at a larger scale, previous findings5 of 18 cases of oligohydramnios in 30 pregnancies (60.0%). Here, ERBB2 is linked to oligohydramnios.